Share

Contacts

  • Quotes

    This issuance of this patent is an important part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products
    Peter Wolpert, Moberg Pharma’s CEO
    We are pleased with the agreement with Caret Pharma LLC. which enables us to increase focus on the core Moberg Pharma portfolio. We have now successfully divested both non-core brands included in the acquisition from Prestige Brands, while the acquired strategic brands are developing well
    Peter Wolpert, CEO Moberg Pharma
    Kerasal Nail® reached a market share of 29%, while at the same time, we have expanded distribution for both Dermoplast® and New Skin®. Enrolment for the MOB-015 study has taken longer than expected but is accelerating after corrective measures have been implemented
    Peter Wolpert, CEO Moberg Pharma
    The successful results from patients with nail psoriasis, and for the study as a whole, make a stronger selling point for Kerasal Nail®/ Emtrix®, something which is of great importance for future efforts in all markets
    Peter Wolpert, CEO of Moberg Pharma
    This is our most recent acquisition and we are pleased that the integration is progressing according to plan. The distribution gains provide excellent opportunities to build on the brand equity of Dermoplast® in the years to come
    Jeff Vernimb, GM of Moberg Pharma North America
    We are excited about the prospects for Zanmira Nail® in Japan, which has the potential to become a major market for Moberg Pharma. We look forward to the continued collaboration with CMIC in Japan, as well as with Menarini in the other markets of the Asia-Pacific region
    Peter Wolpert, CEO of Moberg Pharma
    The divestment is made for personal financial reasons and I don’t intend to sell additional shares. I have great faith in the prospects for Moberg Pharma and I look forward to continuing to build the company
    Peter Wolpert, CEO of Moberg Pharma
    We see excellent opportunities to build on the brand equity of New Skin®. This a market leading brand with exciting prospects for growth, as shown with the increased distribution
    Jeff Vernimb, GM of Moberg Pharma North America
    We highly appreciate the support provided by our bondholders and the large interest for this tap issue. As a result, the issue has been placed at a premium to the nominal amount and we have secured the capital needed to complete the acquisition of DermoPlast®. From January 2017, DermoPlast® is expected to contribute significantly to our profitability and operative cash flow
    Peter Wolpert, CEO of Moberg Pharma
    I am proud to announce the acquisition of DermoPlast®. After thorough evaluation and diligence I am very pleased that we have now secured financing to be able to complete this important acquisition for Moberg Pharma. The transaction is expected to contribute positively to our sales and profitability and contribute to our long-term financial target to deliver profitable growth and an EBITDA-margin of 25 percent
    Peter Wolpert, CEO of Moberg Pharma
    The Board of Directors of Moberg Pharma is very pleased with the acquisition of DermoPlast®. Through the acquisition, the company strengthens its portfolio of strategic brands – DermoPlast® fits perfectly into the company's focus on topical products. We can also fully utilize the existing organization and sales channels in the U.S. After the acquisitions, the company now has three major strategic brands – Kerasal Nail®, DermoPlast® and New Skin® – which increases the diversification and thus strengthens the company. The focus over the coming year is to successfully integrate acquisitions and to strengthen the positioning of our portfolio and to continue to create value through the advancement of our development pipeline
    Thomas Eklund, chairman of Moberg Pharma
    The opportunity to acquire DermoPlast® is very attractive. The acquisition is in line with our strategy and leverages our existing infrastructure and sales channels in the U.S. in an excellent way. DermoPlast® brings increased economies of scale and complements our portfolio with a strong and profitable dermatology brand. We are very pleased with the opportunity to complete this transaction, which is expected to contribute positively to both our sales and profitability and thereby to our long term financial target to deliver profitable growth and an EBITDA margin of 25 per cent
    Peter Wolpert, CEO of Moberg Pharma
    We appreciate the increased flexibility which our bondholders have granted the company and hence enhanced our possibilities to optimally finance accretive acquisitions
    Peter Wolpert, Moberg Pharma’s CEO
    We are pleased with the agreement with Strides which enables us to further focus on our strategic assets and M&A activities
    Peter Wolpert, CEO Moberg Pharma
    We had very positive momentum in Q3. The team has already now delivered on all major milestones for 2016
    Peter Wolpert, CEO of Moberg Pharma
    This patent provides Moberg with important intellectual property protection for BUPI, our lozenge formulation of bupivacaine for pain management of oral mucositis in cancer patients
    Peter Wolpert, CEO of Moberg Pharma
    This issuance of this patent is an important milestone for the BUPI development program and part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products.
    Peter Wolpert, CEO of Moberg Pharma
    The start of the patient enrollment in the Phase 3 program for MOB-015 is a major milestone for Moberg Pharma
    Peter Wolpert, CEO of Moberg Pharma
    Our long-term vision is to become a global leader in onychomycosis and we believe that MOB-015 has the potential to establish a new standard of care. The Phase 3 studies have been designed to support registration in North America, Europe and other major markets
    Peter Wolpert, CEO of Moberg Pharma
    This is a significant step forward in the further development of MOB-015. We are committed in our pursuit to bring an efficacious and safe topical treatment in the form of MOB-015 to patients suffering from nail fungus
    Kjell Rensfeldt, VP Research and Development of Moberg Pharma AB
    We are pleased with the significant interest from Swedish and other Nordic investors. Our maintained activity in the corporate bond market strengthens our capacity to raise non-dilutive financing and we are very pleased to have been able to issue these subsequent bonds at a premium to the nominal amount, despite recent market turbulence
    Peter Wolpert, CEO of Moberg Pharma AB
    This acquisition is in line with our strategy to add critical mass to Moberg’s U.S. operations as well as a leading topical brand to our core dermatology franchise. This transaction is an excellent use of the proceeds from the bond loan issue earlier this year and the funds released in the recent divestment of non-core brands to Strides Pharma Inc. The acquired brands will immediately contribute significantly to our sales and earnings and also to our long term financial goal of delivering profitable growth and an EBITDA margin of 25%. In three recent transactions, we have established relationships with major OTC players - Bayer, Chattem and now Prestige - which also will facilitate future transactions
    Peter Wolpert, CEO of Moberg Pharma AB
    We see excellent opportunities to build on the brand equity of New Skin. This a market leading brand with exciting prospects for growth. We will leverage our Innovation Engine to further strengthen the future value proposition of this brand as well as Fiber Choice and PediaCare to consumers and retailers
    Jeff Vernimb, GM of Moberg Pharma North America
    We are very pleased with the progress of the global launch of Kerasal Nail/Emtrix. The recent and immediate success achieved in important markets like Japan and Taiwan is indicative of the significant potential of Kerasal Nail/Emtrix in this dynamic region. We expect the region to become an even more important contributor to revenues and earnings
    Martin Ingman, VP Sales & Marketing Moberg Pharma AB
    The overwhelmingly positive consumer response to the brand repositioning and new marketing campaign launched in early 2016 confirms our hypothesis that the clinically proven visible difference that Kerasal Nail provides is a key benefit that consumers value highly. Kerasal Nail continues to be an important growth driver in the OTC segment with a meaningful message able to breakthrough and be heard
    Jeff Vernimb, GM of Moberg Pharma North America.
    These patents are exceptionally important to Moberg since they secure IP rights for MOB-015 until at least 2032 in various markets worldwide where we plan to sell or license this product, once approved. They represent a strong addition to our portfolio which now includes 12 issued patents and 27 pending patent applications worldwide in four different patent families
    Peter Wolpert, CEO of Moberg Pharma AB
    We are thrilled by the prospect of developing BUPI through Phase III and subsequently making the product available to patients in great need of improved pain relief. The de-risked strategy significantly reduces our investment requirement, while allowing us to retain commercial rights in all major territories as well as rights to data from the two Phase III studies. This strategy will enable Moberg Pharma to build substantial value in the BUPI asset for its shareholders
    Peter Wolpert, CEO of Moberg Pharma AB
    We are excited to enter this collaboration with Cadila Pharmaceuticals and to leverage our combined innovation capabilities as well as Cadila’s clinical, manufacturing and commercialization capabilities in India. Establishing innovative partnership models supports Moberg’s commitment to bringing novel treatments to patients in underserved niches
    Peter Wolpert, CEO of Moberg Pharma AB
    In line with our philosophy to bring innovative solutions to unmet medical needs, we are delighted to partner with Moberg Pharma on BUPI to bring more efficacious pain management to patients with oral mucositis, a condition with high prevalence in India
    Dr. Rajiv I. Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd., India
    We are pleased with the agreement with Strides which enables us to further focus on our strategic assets and M&A activities. The transaction also results in a capital gain for our shareholders
    Peter Wolpert, CEO Moberg Pharma
    We are pleased with the large interest among Swedish and Nordic investors for the bond loan, despite challenging market conditions. The access to the corporate bond market and non-dilutive financing strengthens our financial position further and is an important step in the financing of the company’s growth and acquisition strategy
    Peter Wolpert, CEO Moberg Pharma
    Moberg Pharma has in five years grown from zero to close to SEK 300 million in revenue and created a profitable business. We are in a position to strengthen the company and create considerable value for our shareholders. Short-term, we make significant investments while maintaining our long-term financial goal of achieving an EBITDA margin of at least 25 percent
    Peter Wolpert, CEO Moberg Pharma
    This study shows that BUPI provided additional pain reduction to levels below VAS 40 in a patient population for which it is difficult to achieve adequate pain relief. Developing a new formulation of bupivacaine, intended for self-administration at home, requires a thorough evaluation of the safety profile of the product. Moberg Pharma will now proceed with in-depth analyses of all other data collected in this study, in order to guide further clinical development of BUPI
    Kjell Rensfeldt, VP Research and Development at Moberg Pharma
    In total, 32 patients meeting the amended inclusion criteria have now completed the study. We expect to announce topline data in January
    Kjell Rensfeldt, VP R&D of Moberg Pharma AB
    Strong performance, with our distributor sales in Asia as a key driver, resulted in a third quarter with topline growth and continued improvement in profitability which doubled compared to last year
    Peter Wolpert, CEO of Moberg Pharma
    I am very pleased that we jointly agreed to focus our partnership on the majority of markets where it has been successful. We are evaluating options to launch by ourselves or through other distributors in the now released markets to further leverage the potential of Emtrix® in Europe
    Peter Wolpert, CEO of Moberg Pharma AB
    We are excited to further build on the synergies being generated from our current collaboration with Colep. This agreement leverages Colep’s expertise and manufacturing capabilities for the late-stage development and subsequent commercialization of MOB-015. For Moberg, this agreement reduces our development expenses for phase 3 and establishes an attractive supply cost for the commercial phase. Forming innovative partnership models supports Moberg’s commitment to bringing novel treatments to patients in underserved niches, and further advances our vision to become the leading player in onychomycosis
    Peter Wolpert, CEO of Moberg Pharma AB
    We are delighted to expand our successful collaboration with Moberg Pharma to now include MOB-015. We decided to co-invest in the project based on the significant market potential for MOB-015 as well as the strong track record established by the other Moberg products Colep currently manufactures
    Ludwig Bastiaansen, Managing Director, Healthcare Division, Colep
    The granted Kerasal Nail patents provide long-term intellectual property protection for our flagship product. It also reconfirms our commitment to bringing innovation to underserved niches and our long term goal to be the leading player in nail fungus
    Peter Wolpert, CEO of Moberg Pharma AB
    We are very pleased with the progress and that the launch of Kerasal Nail now has started in China. Kerasal Nail has significant potential in the region. Assuming successful launches, we expect the region to become an important contributor to revenues and earnings from 2015 and onwards
    Peter Wolpert, CEO of Moberg Pharma AB
    Adding Balmex to Moberg’s U.S. portfolio is a great fit, within our core area of topical dermatology. We are continuously evaluating deal opportunities to further leverage our U.S. sales and marketing infrastructure. This deal contributes immediately to our sales and earnings and to our long term financial goal of delivering profitable growth and an EBITDA margin of 25% from 2016
    Peter Wolpert, CEO of Moberg Pharma AB
    We see excellent opportunities to build on the brand equity of Balmex and utilize our Innovation Engine to further strengthen the future value proposition of the brand to consumers and retailers
    Jeff Vernimb, GM of Moberg Pharma North America
    The granted European patent in addition to the recently approved U.S. patent strengthens the value of our MOB-015 asset. We continue to progress discussions with potential partners and are preparing for start of phase III in 2016. The rapid growth of the value of the U.S. Rx onychomycosis market during the last 9 months further strengthens the attractiveness of the indication. Based on the phase II results, MOB-015 has the potential to become superior to other topical treatments, including the recently launched products.
    Peter Wolpert, CEO of Moberg Pharma AB
    The new Kerasal Nail patent provides long-term intellectual property protection for our flagship product in the U.S. It also reconfirms our commitment to bringing innovation to underserved niches and our long term goal to be the leading player in nail fungus
    Peter Wolpert, CEO of Moberg Pharma AB
    We are impressed by Menarini's launch of Emtrix in Malaysia which resulted in a great response from pharmacies as well as consumers. The positive response confirms our view that there is a huge unmet need for a new and better product in the nail fungus category and that the sales potential in the region is significant
    Peter Wolpert, CEO of Moberg Pharma AB
    We are excited to add Walmart to the list of major U.S. retailers who already stock Domeboro and particularly pleased to gain distribution in advance of the spring season. Currently snow is blanketing much of the country, but we know warm weather will soon be here as will the inevitable skin rashes caused by poison ivy and other irritants. Since Domeboro is a strategic brand for Moberg Pharma, expanding the distribution with Walmart is a high priority which will contribute to sales and earnings in 2015
    Jeff Vernimb, General Manager of Moberg Pharma North America
    We are excited to launch our next innovation in foot care. Consistent with our strategic goal to be number one in products related to nail fungus, we continue to seek new product innovations that offer unique, convenient and highly effective solutions for our consumers and retail partners. Until now, there has been no product on the market that addresses both these needs, marketed and promoted as a single convenient solution. Kerasal Complete Care is a dual-pack kit that provides a daily single regimen for addressing both needs
    Peter Wolpert, CEO of Moberg Pharma AB
    The approval of the U.S. patent for MOB-015 is a key milestone in our strategic goal to become the No. 1 player in products relating to nail fungus. We are moving forward in discussions with potential industrial as well as financial partners for the phase III program, with the aim of starting phase III in 2016
    Peter Wolpert, CEO of Moberg Pharma AB
    I am very pleased to expand our collaboration with the Menarini Group through this agreement with Berlin-Chemie – a leading marketer in Eastern Europe. The Russian market has significant long-term potential for Moberg’s products
    Peter Wolpert, CEO of Moberg Pharma AB
    We are excited about the progress that Menarini Asia-Pacific has made in registration and launch preparation activities. Kerasal Nail® has significant potential in the region. Assuming successful launches, the region will be an important contributor to revenues and earnings from 2015 and onwards
    Peter Wolpert, CEO of Moberg Pharma AB
    Pick a time period -
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media